Figure 1.
Progression-free survival (PFS) of patients carrying EGFR mutations treated with gefitinib in different mutation groups. S-A+, sequencing negative but ARMS positive; S+A+, sequencing positive and ARMS positive; log-rank, P=0.009; ARMS, Scorpion amplification refractory mutation system.